Last updated: 24 June 2024 at 4:12pm EST

Catherine Owen Net Worth




The estimated Net Worth of Catherine E. Owen is at least 1.82 千$ dollars as of 13 June 2024. Ms. Owen owns over 1,976 units of OptiNose Inc stock worth over 1,818$ and over the last 4 years she sold OPTN stock worth over 0$. In addition, she makes 0$ as Director at OptiNose Inc.

Ms. Owen OPTN stock SEC Form 4 insiders trading

Catherine has made over 1 trades of the OptiNose Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she exercised 1,976 units of OPTN stock worth 1,818$ on 13 June 2024.

The largest trade she's ever made was exercising 1,976 units of OptiNose Inc stock on 13 June 2024 worth over 1,818$. On average, Catherine trades about 220 units every 0 days since 2020. As of 13 June 2024 she still owns at least 1,976 units of OptiNose Inc stock.

You can see the complete history of Ms. Owen stock trades at the bottom of the page.





Catherine Owen biography

Catherine E. Owen serves as Director of the Company. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. She joined BMS in 2019 from Johnson & Johnson, where she served most recently as President of Janssen Immunology North America, which launched new products in Crohn’s disease and psoriasis and led the development of J&J’s biosimilars strategy. Prior to leading Immunology, she was the President of the Infectious Diseases business in the US, responsible for the HIV, RSV, Flu, and Hepatitis B pipeline. Prior to that she worked in various functions and businesses at J&J and led the launches of multiple products in both Europe and the US. Catherine began her career in the pharmaceutical industry in 1992 at AstraZeneca in London as a production support pharmacist. Catherine earned her Bachelor of Science degree in pharmacy from the University of Manchester and completed her registered pharmacy degree and was a member of the Royal Pharmaceutical Society, MRPhs. In 2019, in recognition of her efforts as a developer of talent, the Healthcare Businesswomen's Association (HBA) named Owen an HBA Luminary.



What's Catherine Owen's mailing address?

Catherine's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at OptiNose Inc

Over the last 19 years, insiders at OptiNose Inc have traded over 144,654,703$ worth of OptiNose Inc stock and bought 116,688 units worth 814,936$ . The most active insiders traders include Sriram VenkataramanCapital Partners Ii Gp, Llc...Rajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of 106,645$. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth 7,803$.



What does OptiNose Inc do?

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo



What does OptiNose Inc's logo look like?

OptiNose Inc logo

Complete history of Ms. Owen stock trades at Agios Pharmaceuticals Inc、OptiNose Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
13 Jun 2024 Catherine E. Owen
ディレクター
オプション行使 1,976 46.77$ 92,418$
13 Jun 2024
1,976


OptiNose Inc executives and stock owners

OptiNose Inc executives and other stock owners filed with the SEC include: